RU School Of Osteopathic Medicine

RU School Of Osteopathic Medicine, a state-controlled institution of higher learning and subsidiary of Rowan University headquartered in Stratford, New Jersey, acts as a prime recipient of federal grants and prime contractor for tuition and medical education services to the Department of the Navy, with 91% of awards held as prime positions across a portfolio spanning medical education, biomedical research, and public health workforce development.

RU School Of Osteopathic Medicine operates as a non-profit educational institution with no SBA set-aside designations, competing full-and-open across federal funding mechanisms. The school's federal footprint centers on two distinct capability streams: medical education and training services for Navy medical personnel, and biomedical and behavioral health research spanning neuroscience, substance use disorders, mental health, suicide prevention, and community health initiatives. As the largest medical school in New Jersey, the institution also delivers workforce training programs in community health worker certification, peer recovery specialist training, and provider clinical support curricula targeting underserved and high-need populations in the tri-state region.

The Department of the Navy Bureau of Medicine and Surgery dominates the customer concentration, accounting for 34 awards (with $3.8 million combined potential value) — nearly 27% of the total award count — through a single-award Basic Ordering Agreement (BOA N0018913GZ006) running through September 2034. Under this BOA, RU School Of Osteopathic Medicine receives repeated firm fixed-price delivery orders for tuition and fees supporting Navy medical personnel training, with individual delivery orders ranging from approximately $24,674 to $303,010. Recent examples include a $134,156 delivery order awarded December 11, 2025, and a $146,791 delivery order awarded July 1, 2025, both for medical education services. A second Navy BOA (N0018924GZ015) carries three additional task orders valued at $524 thousand combined. Beyond the Navy, customer concentration spans 31 federal agencies, with the Department of Health and Human Services dominating the research and workforce development grant portfolio through the Substance Abuse and Mental Health Services Administration (SAMHSA), the Health Resources and Services Administration Bureau of Health Professionals, the National Institutes of Health (National Institute on Aging, National Institute of General Medical Sciences, National Institute on Deafness and Other Communication Disorders, National Institute of Neurological Disorders and Stroke, National Institute of Mental Health, National Institute on Drug Abuse, National Cancer Institute, National Heart Lung and Blood Institute), the Office of the Assistant Secretary for Health, and the Veterans Health Administration.

The research grant portfolio encompasses over 30 prime awards totaling approximately $4 million in combined potential value as represented in the award universe, with recent representative grants including a $599,935 award from SAMHSA for trauma-focused cognitive behavioral therapy training for youth with comorbid PTSD and depression (CFDA 93.532), a $2.29 million award from the National Institute on Deafness and Other Communication Disorders for hedgehog signaling research in postnatal tongue development (CFDA 93.173), a $526,953 award from the National Institute on Aging for neural circuits mediating motivation deficits in Alzheimer's disease (CFDA 93.866), and a $423,708 award from the National Institute on Drug Abuse for fentanyl-xylazine drug mixture cardiorespiratory research (CFDA 93.279). Workforce development grants include a $750,000 Veterans Affairs suicide prevention grant (CFDA 64.055) and multiple Bureau of Health Professionals awards supporting medical student training in primary care, substance use disorder treatment, disability care, and geriatrics.

Activity has modulated across recent years — 12 awards in 2022 rising to 16 in 2024, with 9 in 2025 and 2 to date in 2026 — with 17 awards completing within the next twenty-four months representing recompete opportunity. The subcontractor footprint is minimal (9% of awards), with RU School Of Osteopathic Medicine serving as a sub-recipient on grants from Tulane University (neuropsychological data design), Johns Hopkins University (alpha7 nicotinic receptor imaging), UCLA (SARS-CoV-2 transcription research), Northeast Ohio Medical University (videofluoroscopic data analysis), and the Allegheny Singer Research Institute (trauma-focused CBT training coordination), alongside sub-awards from the New Jersey Department of Human Services under state opioid response programs and COVID-19 emergency funding. Place of performance concentrates in Stratford, New Jersey, with subordinate training and clinical rotation sites across southern New Jersey counties and partnerships extending to West Virginia and Pennsylvania for regional public health workforce initiatives.